Sign In
Buy BIIB
$196.45
+0.490 (+0.250%)
At Close: Jun 04, 2026
Should You Buy Biogen Stock After Its Latest Alzheimer's Disease Drug Approval?
05:55am, Tuesday, 10'th Jan 2023
There's more to the story with Biogen after receiving good news for Leqembi.
Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know
11:15pm, Monday, 09'th Jan 2023 Zacks Investment Research
Biogen Inc. (BIIB) closed at $274.72 in the latest trading session, marking a -1.62% move from the prior day.
Biogen Inc. (BIIB) 41st Annual J.P. Morgan Healthcare Conference (Transcript)
05:30pm, Monday, 09'th Jan 2023
Biogen Inc. (NASDAQ:BIIB ) 41st Annual J.P. Morgan Healthcare Conference Call January 9, 2023 2:15 PM ET Company Participants Chris Viehbacher - CEO Conference Call Participants Chris Schott - J.P.
Biogen (BIIB), Eisai's Lecanemab Gets FDA Nod for Alzheimer's
03:04pm, Monday, 09'th Jan 2023 Zacks Investment Research
FDA approves Biogen (BIIB) and Eisai's lecanemab on an accelerated basis. Eisai filed a supplemental biologics license application (sBLA) to the FDA to get a traditional approval for Leqembi.
‘There is a lot that's underestimated at Biogen': CEO Viehbacher
11:35am, Monday, 09'th Jan 2023
Shares of Biogen Inc (NASDAQ: BIIB) have gained nearly 45% since late September but CEO Christopher Viehbacher says there's still “a lot that's underestimated” at Biogen. Highlights from CEO's
FDA approves treatment for people with mild forms of Alzheimer's
03:59pm, Saturday, 07'th Jan 2023 MarketWatch
Leqembi, which was developed by Eisai and Biogen, will cost about $26,000 a year
FDA approves Biogen, Eisai Alzheimer's drug
07:10pm, Friday, 06'th Jan 2023
An Alzheimer's drug from Biogen and Eisai has received accelerated approval from the Food and Drug Administration, the companies and agency announced Friday.
FDA approves Biogen-Eisai Alzheimer's drug, China in talks to make Pfizer Paxlovid generic
05:33pm, Friday, 06'th Jan 2023
Yahoo Finance health care reporter Anjalee Khemlani highlights the progress on Biogen-Eisai's collaborative Alzheimer's treatment drug and China's plans to distribute Pfizer's Paxlovid pill.
FDA approves Biogen's Alzheimer's drug
02:59pm, Friday, 06'th Jan 2023
CNBC's Meg Tirrell reports on Biogen and the company receiving FDA approval for an Alzheimer's treatment.
1 Stock Defying the Downturn to Buy, and 1 to Avoid
02:53pm, Friday, 06'th Jan 2023 The Motley Fool
These two stocks might go in different directions in the future.
FDA approves treatment for people with mild forms of Alzheimer's
02:41pm, Friday, 06'th Jan 2023
The Food and Drug Administration on Friday granted an accelerated approval to Eisai and Biogen's Alzheimer's disease treatment, which showed in clinical trials that it can slow the progression of the
FDA Approves Eisai and Biogen's New Alzheimer's Therapy
02:37pm, Friday, 06'th Jan 2023
The Food and Drug Administration on Friday approved Eisai and Biogen's Alzheimer's treatment lecanemab, clearing the way for the drug to be prescribed to patients and opening what will likely be a lon
The FDA just approved a new Alzheimer's drug that's set to be a blockbuster
02:21pm, Friday, 06'th Jan 2023
The new drug, called Leqembi, slowed the rate of cognitive decline in Alzheimer's patients by 27%.
FDA approves Alzheimer's drug that slowed cognitive decline in clinical trial
02:11pm, Friday, 06'th Jan 2023
The FDA's decision comes after clinical trial results indicated that lecanemab slows cognitive decline somewhat in people with mild impairment from Alzheimer's.
Jefferies' Michael Yee on Biogen as FDA could be on the verge of approving Alzheimer's drug
02:09pm, Friday, 06'th Jan 2023
Michael Yee, Jefferies managing director, joins 'The Exchange' to discuss biotech and the FDA's looming decision on Biogen's second Alzheimer's drug.
